Logo

American Heart Association

  208
  0


Final ID:

Discussant: PALISADE

  • Shapiro, Michael  ( Wake Forest Univ School of Medicine , Winston Salem , North Carolina , United States )
  • Author Disclosures:
    Michael Shapiro: DO have relevant financial relationships ; Consultant:Amgen:Active (exists now) ; Advisor:Arrowhead:Active (exists now) ; Advisor:Merck:Active (exists now) ; Consultant:Regeneron:Active (exists now) ; Advisor:Ionis:Active (exists now) ; Advisor:Agepha:Past (completed) ; Consultant:Novartis:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Featured Science: Novel Approaches to Managing Lipid Risk

Saturday, 11/16/2024 , 01:30PM - 02:45PM

Featured Science

More abstracts on this topic:
Long-term Efficacy of Lerodalcibep in 1,468 Patients at Very High and High Risk for CVD in the 72 week Open-Label Extension Trial

Kereiakes Dean, Fourie Nyda, Scott Russell, Asprusten Emil, Yalim Zafer, Vest Jeff, Kallend David, Stein Evan

Novel Lipid Targets and Vascular Outcomes

Libby Peter, Ginsberg Henry

You have to be authorized to contact abstract author. Please, Login
Not Available